All Stories

  1. PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
  2. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data
  3. Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study
  4. PET imaging in Alzheimer's disease